Dr Andrew Reynolds is a Senior Director Scientist at AstraZeneca, Cambridge, UK. Andrew completed his PhD at the CRUK London Research Institute in 2002, followed by a Postdoctoral Research Fellowship at Barts Cancer Institute (BCI) in London from 2002 to 2007. He then held a post as a Group Leader at the Institute of Cancer Research (ICR) in London from 2007 to 2016, before then joining AstraZeneca in 2016. His current research at AstraZeneca is focused on premalignant disease and cancer prevention.